← Back to Search

18F-NOS PET/CT Scan for Parkinson's Disease

Phase < 1
Waitlist Available
Led By Jacob Dubroff, MD
Research Sponsored by University of Pennsylvania
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Diagnosed with Parkinson's Disease at least 3 year prior to enrollment.
Participants will be 18-75 years of age.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 years
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing whether a PET scan can help diagnose or monitor Parkinson's disease by measuring inflammation in the brain.

Who is the study for?
This trial is for people aged 18-75 with Parkinson's disease or healthy individuals interested in brain inflammation research. Participants must understand the study and agree to its procedures. Those with neuropsychiatric disorders can join if it doesn't risk their safety or participation, as judged by an investigator.
What is being tested?
The study tests a PET/CT scan using a tracer called 18F-NOS to detect brain inflammation, which could help diagnose or monitor Parkinson's disease treatment effectiveness.
What are the potential side effects?
While not explicitly listed, potential side effects may include discomfort from the injection of the tracer, allergic reactions to the imaging drug, and exposure to radiation from the PET/CT scan.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I was diagnosed with Parkinson's Disease over 3 years ago.
Select...
I am between 18 and 75 years old.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Characterize the uptake of [18F]NOS
Secondary study objectives
Compare patterns of uptake
Compare peripheral blood inflammatory biomarkers

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: Patient with Parkinson DiseaseExperimental Treatment1 Intervention
Subject should have a history of diagnosis of probable idiopathic PD derived from UK Brain Bank Diagnostic criteria per neurologist review. Subject must have been diagnosed with Parkinson's Disease at least 3 year prior to enrollment.
Group II: Healthy ControlExperimental Treatment1 Intervention
Subject must be a Healthy.

Find a Location

Who is running the clinical trial?

University of PennsylvaniaLead Sponsor
2,073 Previous Clinical Trials
42,714,245 Total Patients Enrolled
Jacob Dubroff, MDPrincipal InvestigatorUniversity of Pennsylvania

Media Library

[18F]NOS Clinical Trial Eligibility Overview. Trial Name: NCT04062526 — Phase < 1
Parkinson's Disease Research Study Groups: Patient with Parkinson Disease, Healthy Control
Parkinson's Disease Clinical Trial 2023: [18F]NOS Highlights & Side Effects. Trial Name: NCT04062526 — Phase < 1
[18F]NOS 2023 Treatment Timeline for Medical Study. Trial Name: NCT04062526 — Phase < 1
~1 spots leftby Aug 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top